DAZL

Across TCGA pan-cancer cohorts, DAZL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DAZL data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher DAZL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DAZL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, KIRC, and LUSC are the cancer types where DAZL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.191	0.833	<.001	27	view →
KIRC	OS	Median	All	0.263	0.810	.015	12	view →
LUSC	DFS	Median	II,III,IV	0.124	0.709	<.001	12	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
UCEC	DFS	Median	All	0.921	0.633	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DAZL–BRCA (OS)

Open the BRCA breakdown →